Follow The Filings

AIDX 20/20 Biolabs

20/20 Biolabs earnings company data as of 6:08 AM ET 11/17

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS -0.06 — —
Rev $891.0K $380.0K Miss
FY2026 Q2 14 Aug EPS -0.12 — —
Rev — $700.0K —

Insider trades

Open-market buys and sales by AIDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AIDX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 5 conversions.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
10-Q QUARTERLY REPORT
8-K 2.02,9.01
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
DEF 14A DEFINITIVE PROXY STATEMENT
8-K 5.07
8-K 3.01
8-K 7.01,9.01
8-K 5.07
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
8-K 2.02,9.01
424B3 PROSPECTUS SUPPLEMENT
424B3 PROSPECTUS SUPPLEMENT
10-Q QUARTERLY REPORT
8-K 7.01,9.01
8-K 1.01,3.01,9.01
8-K 7.01,9.01
DEF 14A DEFINITIVE PROXY STATEMENT
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
8-K 3.03,5.03,9.01
424B3 PROSPECTUS SUPPLEMENT
424B3 PROSPECTUS SUPPLEMENT
8-K 2.02,9.01
10-Q QUARTERLY REPORT
8-K 1.01,9.01
424B3 PROSPECTUS SUPPLEMENT

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf